phenylmalonic acid monoisopropyl ester | 24132-79-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: phenylmalonic acid monoisopropyl ester
• 英文别名: isopropyl hydrogen phenylmalonate；3-oxo-2-phenyl-3-propan-2-yloxypropanoic acid
• CAS: 24132-79-4
• 化学式: C₁₂H₁₄O₄
• 分子量: 222.241
• InChiKey: GRJZDSSKDSLMSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-氨基青霉烷酸 、 phenylmalonic acid monoisopropyl ester 生成 6β-((Ξ)-2-isopropoxycarbonyl-2-phenyl-acetylamino)-penicillanic acid
  参考文献：
  名称：

  Preparation, hydrolysis, and oral absorption of .alpha.-carboxy esters of carbenicillin

  摘要：

  Twelve alpha-carboxy esters of carbenicillin, a parenteral broad spectrum semisynthetic penicillin, were synthesized and examined as potential oral carbenicillin derivatives. The rates at which the esters were hydrolyzed in vitro to carbenicillin by animal and human tissues were compared and the carbenicillin serum levels arising after oral administration of the esters were measured in squirrel monkeys and human volunteer subjects. The alpha-carboxyphenyl ester of carbenicillin [carfecillin (British Pharmacopoeia approved name), BRL 3475] WAS SELECTED FOR FURTHER STUDY AND IS PRESENTLY UNDERGOING CLInical trial.

  DOI：

  10.1021/jm00236a013
• 作为产物：
  描述：

  苯丙二酸 在 氯化亚砜 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以60% (as reported)的产率得到phenylmalonic acid monoisopropyl ester
  参考文献：
  名称：

  Anticholinergic compounds, composititons and methods of treatment

  摘要：

  该公式化合物的变量定义在规范中。这些化合物及其盐是软性抗胆碱能/抗分泌剂，特别适用于瞳孔扩大剂和抗汗剂。

  公开号：

  US05223528A1

文献信息

• Anticholinergic compounds, compositions and methods of treatment
  申请人：University of Florida

  公开号：US05610188A1

  公开（公告）日：1997-03-11

  Compounds of the formula ##STR1## wherein the variables are defined in the specification. The compounds and their salts are soft anticholinergic/antisecretory agents especially useful as mydriatics and as antiperspirants.

  该式的化合物及其盐是软性抗胆碱能/抗分泌剂，尤其适用于瞳孔扩大剂和止汗剂。其中变量在规范中定义。
• Anticholinergic compounds, pharmaceutical compositions and method of treatment
  申请人：UNIVERSITY OF FLORIDA

  公开号：EP0238982A1

  公开（公告）日：1987-09-30

  A compound having the formula Wherein: R1 is the esterification residue of a pharmaceutically acceptable non-toxic, substituted or unsubstituted, straight cyclic or branched chain alcohol (R1-OH) having from 1 to 8 carbon atoms such that the ester group, CORR1, is metabolically hydrolyzable to the free alcohol, R1-OH, and a non-toxic metabolite of said compound following administration thereof to a human or non-human animal; R2 is a substituted or unsubstituted aryl, cycloalkyl, or alkyl group having from 1 to 8 carbon atoms; R3 is H or R2; n is an integer from 0 to 4; wherein R8 is H or straight or branched chain alkyl having from 1 to 5 carbon atoms; wherein R9 and R10 may be the same or different and may be H or lower alkyl having from 1 to 5 carbon atoms; (̵S)̵; (̵EO)̵ or (̵NH)̵; m is an integer from 0 to 4; wherein R5 and R6 may be the same or different and are alkyls having from 1 to 5 carbon atoms; wherein R5, R6 and R7 may be the same or different and are alkyls having from 1 to 5 carbon atoms; ortho-, meta- or para-substituted alkyl pyridine, wherein Z is an integer from 0 to 3 or wherein said empty valences are filled with groups to produce a non-toxic quaternary nitrogen salt and X- is a pharmaceutically acceptable anion. The esters are prepared in two steps to the tertiary compounds and in three steps to the quaternary compounds from the phenyimalonic acid. It is an object of the present invention to provide novel anticholinergic compounds which exhibit anticholinergic properties and which induce mydriasis as well as pharmaceutical compositions and methods of treatment embodying those compounds which are more effective and less toxic than those presently available.

  一种化合物，其化学式为 其中R1 是药学上可接受的、无毒的、取代或未取代的、直链或支链醇（R1-OH）的酯化残基，具有 1 至 8 个碳原子，从而使酯基 CORR1 可在人或非人动物体内代谢水解为游离醇 R1-OH 和所述化合物的无毒代谢物； R2 是具有 1 至 8 个碳原子的取代或未取代的芳基、环烷基或烷基； R3 是 H 或 R2 n 是 0 至 4 的整数； 其中 R8 是 H 或具有 1 至 5 个碳原子的直链或支链烷基； 其中 R9和R10可以相同或不同，可以是H或具有1至5个碳原子的低级烷基；(̵S)̵；(̵EO)̵或(̵NH)̵；m是0至4的整数； 其中 R5 和 R6 可以相同或不同，并且是具有 1 至 5 个碳原子的烷基； 其中 R5、R6 和 R7 可以相同或不同，并且是具有 1 至 5 个碳原子的烷基； 正、偏或对取代的烷基吡啶、 其中 Z 为 0 至 3 的整数或 其中所述空价位用基团填充，以产生无毒的季氮盐，X- 是药学上可接受的阴离子。 从苯丙炔酸到三级化合物的酯类制备分两步进行，到四级化合物的酯类制备分三步进行。 本发明的目的是提供新型的抗胆碱能化合物，这些化合物具有抗胆碱能特性并能诱导瞳孔散大，同时还提供含有这些化合物的药物组合物和治疗方法，这些化合物比现有的化合物更有效且毒性更低。
• Arylidene-heterocyclic derivatives, process for their preparation and their use as tyrisine kinase inhibitors
  申请人：PHARMACIA S.p.A.

  公开号：EP0549348A1

  公开（公告）日：1993-06-30

  The invention relates to compounds of formula wherein Ar is mono-or bicyclic ring system chosen from benzene, naphthalene, tetrahydronaphthalene, quinoline and indole; Het is R is hydrogen, halogen, hydroxy, C₁-C₆ alkoxy, C₂-C₆ acyloxy, cyano, nitro, amino or -COOR₃ in which R₃ is hydrogen or C₁-C₆ alkyl; R₁ is hydrogen, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₂-C₆ acyloxy, cyano, nitro, amino or -COOR₃ in which R₃ is as defined above; R₂ is hydrogen, halogen, hydroxy or C₁-C₆ alkyl; and the pharmaceutically acceptable salts thereof, and wherein when at the same time the (Ar) R₁ R₂ group represents unsubstituted phenyl or 4-chloro-, 4-cyano-, 4-amino- or 3,4-dimethoxy-phenyl and Het is a 4-homophthalimide group, then R is other than hydrogen, which are useful as anti-proliferative agents.

  本发明涉及式化合物 式中 Ar 是单环或双环系统，选自苯、萘、四氢萘、喹啉和吲哚； Het 是 R 是氢、卤素、羟基、C₁-C₆ 烷氧基、C₂-C₆酰氧基、氰基、硝基、氨基或 -COOR₃，其中 R₃ 是氢或 C₁-C₆ 烷基； R₁ 是氢、羟基、C₁-C₆ 烷基、C₁-C₆ 烷氧基、C₂-C₆ 酰氧基、氰基、硝基、氨基或 -COOR₃，其中 R₃ 如上定义； R₂是氢、卤素、羟基或 C₁-C₆烷基；以及它们的药学上可接受的盐，其中当（Ar）R₁ R₂基团同时代表未取代的苯基或 4-氯-、4-氰基-、4-氨基-或 3,4-二甲氧基-苯基且 Het 是 4-高邻苯二甲酰亚胺基团时，则 R 是氢以外的其它基团，它们可用作抗增殖剂。
• US5223528A
  申请人：——

  公开号：US5223528A

  公开（公告）日：1993-06-29
• US5258388A
  申请人：——

  公开号：US5258388A

  公开（公告）日：1993-11-02